Home › Forums › Oral & Maxillofacial surgery › Oral Care Before Cancer Treatment
Welcome Dear Guest
To create a new topic please register on the forums. For help contact : discussdentistry@hotmail.com
- This topic has 2 replies, 3 voices, and was last updated 27/06/2012 at 5:41 pm by drsushant.
-
AuthorPosts
-
16/06/2012 at 3:20 pm #10626DrAnilOfflineRegistered On: 12/11/2011Topics: 147Replies: 101Has thanked: 0 timesBeen thanked: 0 times
Cancer. The New Oxford American Dictionary defines it as “the disease caused by an
Cancer. The New Oxford American Dictionary defines it as “the disease caused by an
uncontrolled division of abnormal cells in a part of the body;” but for the millions of
people it has touched, cancer is so much more.
Cancer is a constant unwanted companion that
opens the door to an unchosen journey and
demands to be followed.
Cancer is a constant
unwanted companion that
alters the well-being of those it afflicts. Modern
treatment regimens given to combat this
disease come with a host of deleterious side
effects, many of which occur in the mouth.
Dentists, dental hygienists and dental auxiliaries
are in a unique and necessary position to make
a positive impact in the lives of patients battling
cancer.
Making a difference begins with a desire to help and a willingness to take a risk. It is
followed by a commitment to learn about the unique oral health care needs of patients
engaged in the fight of their lives and put into practice skills that can literally provide
comfort and hope. We, as dental professionals, can and should be a part of a
comprehensive cancer care team for an ever-growing number of people facing cancer.
DENTAL ONCOLOGY
Dental oncology is a focus of dentistry dedicated to meeting the unique dental and oral
health care needs that arise as a result of cancer therapy. It is an area of oral medicine
devoted to improving the well-being and quality of life of people battling cancer. Dental
oncology goes beyond the scope of general dental treatment to include management of
the soft tissues of the mouth and care for oral side effects specific to cancer therapy. A
dental professional knowledgeable in dental oncology plays an important role
throughout cancer treatment by preventing and managing mouth sores, dental needs,
oral pain and infections. As a member of the patient’s oncology care team, the dental
professional communicates directly with the medical oncologist, radiation oncologist and
other team members to provide optimal comprehensive care before, during, and after
cancer treatments.
Ideally, a patient’s relationship with a dental professional begins as soon as possible
after receiving the diagnosis of cancer. Most of the present-day treatments for cancer
involve the administration of cytotoxic drugs, radiation, myelosuppressive treatments or
some combination thereof. Having a baseline assessment completed before the
implementation of immunosuppressive therapies allows the dental professional to have
a pre-treatment reference point to compare oral and systemic health at future visits.
For the newly diagnosed patient with cancer who has not received regular dental and
oral health care, a prompt visit to the dentist’s office also allows for immediate attention
to unaddressed periodontal issues and unresolved dental needs before
immunosuppression begins. During cancer treatments, bacterial components of
calculus, dental plaque and oral biofilm can easily become vehicles for bacteremia or
oral infections. Properly addressing these oral health concerns at this pre-treatment
stage can prevent or significantly reduce the severity of oral issues that could
complicate or even interrupt the patient’s cancer treatment schedule.
ORAL HEALTH CARE BEFORE CHEMOTHERAPY
Chemotherapy is the treatment of choice for a wide range of cancers. It can be used
either alone or in combination with other treatment modalities. The goal of
chemotherapy is to eradicate the rapidly dividing cancerous cells, but unfortunately
these drugs often cannot differentiate between cancer cells and other types of cells that
divide rapidly under normal conditions within the body. These cells include bone
marrow, hair, and the mucosa of the entire gastrointestinal tract, including the mouth.
Because chemotherapeutic
agents are used to combat
cancers of all types, the dental
professional is needed to care for
patients with most kinds of
cancer, not just malignancies
relevant to structures within the
head or neck.
Because chemotherapeutic
agents are used to combat cancers of all
types, the dental professional is needed to
care for patients with most kinds of cancer,
not just malignancies relevant to structures
within the head or neck.
Optimally, the patient should see a dental
professional well enough in advance so that
all
dental procedures can be completed one
week before beginning chemotherapy. At a
minimum, dental procedures that might
introduce bacteria into the bloodstream
should be completed in this timeframe.
Close communication with the medical
oncologist is of paramount importance as
each member of the oncology team needs
to be aware of the scheduling of all
care
related to the patient. Communication
should include a summary of the present
oral health of the patient, a treatment plan of essential dental care, and an anticipated
timeline of when that care can be completed. The dental professional should also
confirm that the medical colleagues on the oncology team understand the nature of
anticipated oral complications during treatment and be prepared to function as the
expert able to address those oral health issues.
Dental management before chemotherapy should include a thorough baseline dental
and periodontal assessment with close attentions paid to conditions that could be
problematic during times of immunosuppression. Preemptive measures should be
taken to correct or remove any possible sources of oral trauma. These might include
broken teeth or ill-fitting existing restorations or prostheses. Non-restorable teeth that
pose an infection risk in the short term should be extracted. This would include any
tooth affected by severe periodontal disease or deemed to be of endodontic concern.
Partially-erupted third molars should be evaluated and be extracted if they are at risk for
for pericornitis. A thorough dental prophylaxis including scaling and root planing must
be completed. Decreasing the existing intraoral bacterial load is one of the best
preventive services that can be performed for the patient scheduled to undergo
chemotherapy. Carious lesions and tooth-born fractures should be restored. Resin
modified glass ionomer is a good restorative material choice for these patients as
xerostomia is anticipated during cancer treatment. Any orthodontic bands and wires
should be removed and orthodontic treatment postponed until cancer treatment is
completed. Oral hygiene instructions should be reviewed, even for regular dental
patients. Educating about possible or anticipated oral issues and reassuring the patient
and the family they are not alone in this battle builds confidence and strengthens the
dental professional/patient relationship.
ORAL HEALTH BEFORE HEAD AND NECK RADIATION THERAPY
Radiation therapy is routinely used to treat tumors in the head or neck, often in
combination with chemotherapy or immunotherapy. Head and neck radiation, unlike
radiotherapy in other parts of the body, creates issues of particular concern for the
dental professional. Patients undergoing head and neck radiation therapy often
experience permanent life-changing side effects from their cancer treatment.
Understanding these complications at the pre-treatment assessment positions the
dental professional to be of the most service.
The pre-treatment assessment appointment for the patient undergoing head and neck
radiation begins with a full-mouth series of radiographs. A clinical examination including
complete periodontal charting must be combined with the radiographic evaluation to
assess periodontal condition, to diagnose periapical pathology and to identify teeth
requiring immediate attention. All possible sources of intraoral trauma must be
resolved. Because trauma to irradiated bone poses a risk for osteoradionecrosis, the
dental professional must evaluate the current condition of the teeth and periodontium
and anticipate the patient’s ability to maintain meticulous oral hygiene for the remainder
of his or her life, often in challenging intraoral conditions. All non-restorable teeth
should be extracted. Those teeth with moderate to severe periodontal disease and
partially-erupted third molars within the anticipated field of radiation should also be
removed. Other teeth in the planned field of radiation should be evaluated in light of the
patient’s current hygiene status and dental history, the presence of high-risk deleterious
habits or co-morbidities (e.g. smoking and diabetes mellitus), the patient’s commitment
to regular professional dental visits, and the risk of osteoradionecrosis. Any decision by
the patient to refuse to comply with the dental professional’s recommendation should be
well-documented in the patient’s chart. All remaining teeth must be thoroughly cleaned.
Dental impressions should be taken from which fluoride trays can be fabricated for the
patient’s at-home use. The dental professional should counsel the patient and his or
her family concerning the anticipated complications of head and neck radiation therapy
and the life-long changes that must be made in oral health care.
Communication between the dental professional and radiation oncologist is extremely
important. The dentist should understand the anticipated scheduling of radiation
treatments and must know the amount of radiation planned for each of the jaws.
Similarly, the radiation oncologist should be aware of all necessary dental treatment and
the anticipated timeline to complete it. The timing of dental surgery is of utmost
importance: at least 14 days should be available for healing following any surgery
before radiation therapy commences. The dental professional should understand that
tumors of the head and neck are often times fast moving and require expeditious
treatment. Every effort should be made to accommodate head and neck patients for
treatment as soon as possible. There are times, however, when the nature of the tumor
may be such that radiation therapy must be initiated immediately and not allow
adequate time for dental work to be completed. In these cases, dental care should be
postponed until the completion of radiotherapy and the patient has sufficiently
recovered. Dental care should be avoided while the patient is undergoing radiation
therapy, but should be completed as soon after radiotherapy as possible since bone
changes associated with radiation worsen over time.
ORAL HEALTH BEFORE BISPHOSPHONATE THERAPY
Bisphosphonate therapy is used extensively in patients with metastatic bone disease.
These drugs, which include Zometa®(zoledronic acid) and Aredia®(pamidronate), are
administered intravenously through a portacath. They fall into a unique class of drugs
that are characterized by their affinity for bone and the ability to inhibit bone resorption
through decreased osteoclastic activity. Because they limit bone turnover, these drugs
have been implicated in osteonecrosis following dental surgery subsequent to
bisphosphonate therapy. Drug potency and accumulation seem to be important factors
in assessing whether or not a patient is at risk for developing bisphosphonate-related
osteonecrosis of the jaw.
If non-restorable teeth exist in a patient who will be undergoing bisphosphonate therapy,
they should be removed at least 14 days before the introduction of the drug, if possible.
Partially-erupted third molars and teeth with moderate to severe periodontal disease
should be considered for extraction. Precautions similar to those for patients
undergoing head and neck radiation should be considered in evaluating teeth for
possible extraction as the half-life bisphosphonates can exceed ten years. All dental
professionals should be aware that a history of bisphosphonate disclosed in a medical
history should be carefully considered and evaluated to assess the risk for
bisphosphonate-related osteonecrosis of the jaw.
27/06/2012 at 5:23 pm #15655drmithilaOfflineRegistered On: 14/05/2011Topics: 242Replies: 579Has thanked: 0 timesBeen thanked: 0 timesJ. Silvio Gutkind, Ph.D., chief of the Oral and Pharyngeal Cancer Branch of the National Institute of Dental and Craniofacial Research at the National Institutes of Health, and colleagues induced premalignant lesions in laboratory mice and studied the effect of metformin on progression of these lesions to oral cancers.
"We saw strong activity against mTORC1 (mammalian target of rapamycin complex 1), which we know contributes to oral cancers, so this is strong preclinical information that there is a protective effect," said Gutkind.
Metformin is the most widely used treatment for patients with type 2 diabetes, and scientists have started to notice a trend toward cancer reduction in a number of organ sites.
Gutkind and colleagues found that administration of metformin reduced the size and number of carcinogen-induced oral tumoral lesions in mice and significantly reduced the development of squamous cell carcinomas by about 70 to 90 percent.
They found that metformin inhibited mTORC1 function in the basal layer of oral premalignancies and prevented their spontaneous development into head and neck squamous cell carcinomas.
"We clearly saw a direct effect on premalignant lesions," said Gutkind.27/06/2012 at 5:41 pm #15659drsushantOfflineRegistered On: 14/05/2011Topics: 253Replies: 277Has thanked: 0 timesBeen thanked: 0 timesFor the first time, stem cell researchers at the University of Minnesota have coaxed human embryonic stem cells to create cancer-killing cells in the laboratory, paving the way for future treatments for various types of cancers (or tumors). The research will be published in the Oct. 15 issue of the Journal of Immunology.
Researchers generated "natural killer" cells from the human embryonic stem cells. As part of the immune system, natural killer cells normally are present in the blood stream and are play a role in defending the body against infection and against some cancers.
"This is the first published research to show the ability to make cells from human embryonic stem cells that are able to treat and fight cancer, especially leukemias and lymphomas," said Dan Kaufman, M.D., Ph.D., assistant professor of medicine in the Stem Cell Institute and Department of Medicine at the University of Minnesota and lead author of the study.
"We hear a lot about the potential of stem cells to treat conditions such as Parkinson’s disease, diabetes, and Alzheimer’s disease. This research suggests it is possible that we could use human embryonic stem cells as a source for immune cells that could better target and destroy cancer cells and potentially treat infections," Kaufman added.
The results also provided the researchers with a model of how the immune system develops.
Next, the researchers will test whether the human embryonic stem cell-derived natural killer cells can target cancer cells in animal models.
This research was done on two of the federally approved embryonic stem cell lines. Kaufman said, however, that if the research would lead to a treatment for people, new lines would have to be developed. The research was funded by the National Institutes of Health and the American Society of Hematology. -
AuthorPosts
- You must be logged in to reply to this topic.